Key populations brief
Accessed November 2017
Suggested language and usage for tuberculosis communications
First edition
Accessed November 2017
Working Document, September 2017
Guidelines
June 2017
HIV strategic information for impact
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
Recommendations, resources and references
A publication of the Southern African HIV Clinicians Society
Le cancer du col de l’utérus et le cancer du sein constituent de véritables problèmes de santé publique en raison de leur fréquence. A titre d'exemple, environ 275 000 femmes meurent chaque année d’un cancer du col de l’utérus dans le monde et la plupart de ces décès surviennent dans ...des pays à revenu faible (90%) car le diagnostic est souvent fait à des stades avancés de la maladie.
more
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
Topics in Antiviral Medicine 25 Issue 2 May/June 2017
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...d over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. The disease is endemic in 72 countries. In 2016, an estimated total population of 856 million were living in areas with ongoing transmission of the causative filarial parasites and requiring mass drug administration (MDA). Lymphatic filariasis disfigures and disables, and often leads to stigmatization and poverty. Hundreds of millions of dollars are lost annually due to reduced productivity of affected patients. WHO has ranked the disease as one of the world’s leading causes of permanent and long-term disability.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more